Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TECH BIO-TECHNE Corp
- Stocks
- Healthcare
- NASDAQ: TECH
Price (delayed)
$51.79
Market cap
$8.12B
P/E Ratio
62.4
Dividend/share
$0.32
EPS
$0.83
Enterprise value
$8.4B
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's
Highlights
TECH's P/E is 16% below its last 4 quarters average of 73.4 and 7% below its 5-year quarterly average of 66.4
The revenue has grown by 4.7% YoY
BIO-TECHNE's debt has decreased by 14% YoY but it has increased by 7% QoQ
TECH's EPS is down by 35% year-on-year and by 17% since the previous quarter
The net income has decreased by 35% YoY and by 17% from the previous quarter
Key stats
What are the main financial stats of TECH
Market
Valuations
Earnings
Shares outstanding
156.77M
Market cap
$8.12B
Enterprise value
$8.4B
Price to earnings (P/E)
62.4
Price to book (P/B)
4.06
Price to sales (P/S)
6.74
EV/EBIT
47.01
EV/EBITDA
29.02
EV/Sales
6.95
Revenue
$1.21B
Gross profit
$794.81M
Operating income
$171.94M
Net income
$131.67M
EBIT
$178.72M
EBITDA
$289.57M
Free cash flow
$220.76M
Per share
Balance sheet
Liquidity
EPS
$0.83
EPS diluted
$0.83
Free cash flow per share
$1.4
Book value per share
$12.77
Revenue per share
$7.68
TBVPS
$7.83
Total assets
$2.64B
Total liabilities
$626.23M
Debt
$423.5M
Equity
$2.02B
Working capital
$458.04M
Debt to equity
0.21
Current ratio
3.71
Quick ratio
2.23
Net debt/EBITDA
0.98
Margins
Efficiency
Dividend
EBITDA margin
24%
Gross margin
65.8%
Net margin
10.9%
Operating margin
14.2%
Return on assets
4.9%
Return on equity
6.3%
Return on invested capital
13.4%
Return on capital employed
7.2%
Return on sales
14.8%
Dividend yield
0.62%
DPS
$0.32
Payout ratio
38.6%
TECH stock price
How has the BIO-TECHNE stock price performed over time
Intraday
0.72%
1 week
-1.52%
1 month
0.31%
1 year
-35.12%
YTD
-28.1%
QTD
0.66%
Financial performance
How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.21B
Gross profit
$794.81M
Operating income
$171.94M
Net income
$131.67M
Gross margin
65.8%
Net margin
10.9%
BIO-TECHNE's net margin has decreased by 38% YoY and by 17% QoQ
BIO-TECHNE's operating margin has decreased by 36% YoY and by 15% QoQ
The net income has decreased by 35% YoY and by 17% from the previous quarter
The company's operating income fell by 33% YoY and by 14% QoQ
Price vs fundamentals
How does TECH's price correlate with its fundamentals
Growth
What is BIO-TECHNE's growth rate over time
Valuation
What is BIO-TECHNE stock price valuation
P/E
62.4
P/B
4.06
P/S
6.74
EV/EBIT
47.01
EV/EBITDA
29.02
EV/Sales
6.95
TECH's EPS is down by 35% year-on-year and by 17% since the previous quarter
TECH's P/E is 16% below its last 4 quarters average of 73.4 and 7% below its 5-year quarterly average of 66.4
The stock's price to book (P/B) is 46% less than its 5-year quarterly average of 7.5 and 25% less than its last 4 quarters average of 5.4
BIO-TECHNE's equity has decreased by 2.9% from the previous quarter
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 12.7 and 29% lower than the last 4 quarters average of 9.4
The revenue has grown by 4.7% YoY
Efficiency
How efficient is BIO-TECHNE business performance
BIO-TECHNE's return on equity has decreased by 38% YoY and by 17% QoQ
TECH's return on assets is down by 35% year-on-year and by 16% since the previous quarter
TECH's return on sales is down by 30% year-on-year and by 12% since the previous quarter
BIO-TECHNE's ROIC has decreased by 21% YoY and by 10% from the previous quarter
Dividends
What is TECH's dividend history
DPS
$0.32
Dividend yield
0.62%
Payout ratio
38.6%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has decreased by 11% YoY but it has increased by 6% QoQ
The quick ratio has declined by 10% year-on-year and by 9% since the previous quarter
BIO-TECHNE's debt is 79% lower than its equity
TECH's debt to equity is down by 16% year-on-year but it is up by 11% since the previous quarter
BIO-TECHNE's debt has decreased by 14% YoY but it has increased by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.